Engineering bi/multispecifics: from format innovation to safer therapies
01 Dec 2025
Bi/Multispecifics
- How do you decide which bispecific format to use for a particular therapeutic goal?
- To what extent should format decisions be driven by biology of the target versus manufacturability or clinical considerations?
- How do you balance the need for efficacy against the risk of toxicity when selecting targets?
- Which engineering strategies (e.g., conditional activation, logic-gating, pH-dependent binding) have shown the most promise so far?
- What are the biggest hurdles to implementing these safety-enhancing designs in a clinical setting?
- Where do you see the most need for truly disruptive approaches in modality design to achieve safer therapies?
Industry Expert
